• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝性胸水与肝移植后并发症增加或生存不良无关。

Hepatic hydrothorax is not associated with increased complications or poor survival after liver transplantation.

机构信息

Department of Internal Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.

Department of Gastroenterology, Lahey Hospital and Medical Center, Burlington, MA, USA.

出版信息

Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):199-204. doi: 10.1080/17474124.2023.2166929. Epub 2023 Jan 9.

DOI:10.1080/17474124.2023.2166929
PMID:36620933
Abstract

BACKGROUND

Hepatic hydrothorax (HH) is associated with a poor prognosis. Liver transplant (LT) is the best treatment modality. We aim to assess post-LT morbidity and mortality in patients with cirrhosis and HH.

RESEARCH DESIGN AND METHODS

Adult patients with cirrhosis, who underwent LT at our institution from 2015 to 2020, were retrospectively reviewed. Baseline data was obtained at the time of LT. Patients were followed from baseline until the last follow-up or death. Censoring occurred at the time of the last follow-up or death, whichever occurred earlier. Cumulative incidence of outcomes was determined by the Kaplan-Meier method. Short-term post-operative complications were compared between both groups as well.

RESULTS

428 patients had a LT, of which 72 (16.8%) had HH. Most of the baseline characteristics were similar between patients with and without HH; however, patients in the HH group had a higher proportion of pre-operative history of ascites and hepatic encephalopathy. Pre-operative HH was not significantly associated with post-LT mortality (Hazard ratio 1.12, 95% confidence interval 0.54-2.32; P-value 0.76). Patients had similar short-term post-operative complications between both groups.

CONCLUSIONS

LT is an excellent therapeutic option for patients with cirrhosis and HH, with excellent long-term survival without increased morbidity.

摘要

背景

肝性胸水(HH)与预后不良相关。肝移植(LT)是最佳治疗方式。我们旨在评估肝硬化伴 HH 患者 LT 后的发病率和死亡率。

研究设计和方法

回顾性分析 2015 年至 2020 年在我院行 LT 的成年肝硬化患者。在 LT 时获取基线数据。患者从基线随访至最后一次随访或死亡。以最后一次随访或死亡时间为准进行删失。通过 Kaplan-Meier 法确定结局的累积发生率。比较两组患者的短期术后并发症。

结果

428 例患者行 LT,其中 72 例(16.8%)患有 HH。HH 组和无 HH 组患者的大多数基线特征相似;然而,HH 组患者术前有腹水和肝性脑病病史的比例更高。术前 HH 与 LT 后死亡率无显著相关性(风险比 1.12,95%置信区间 0.54-2.32;P 值 0.76)。两组患者短期术后并发症相似。

结论

LT 是肝硬化伴 HH 患者的极佳治疗选择,长期生存率高,且发病率无增加。

相似文献

1
Hepatic hydrothorax is not associated with increased complications or poor survival after liver transplantation.肝性胸水与肝移植后并发症增加或生存不良无关。
Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):199-204. doi: 10.1080/17474124.2023.2166929. Epub 2023 Jan 9.
2
Liver transplantation for refractory hepatic hydrothorax is associated with a greater survival benefit compared to other complications of cirrhosis.肝移植治疗难治性肝性胸水的生存获益优于肝硬化的其他并发症。
Liver Transpl. 2024 Feb 1;30(2):142-150. doi: 10.1097/LVT.0000000000000218. Epub 2023 Jul 17.
3
Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis.经颈静脉肝内门体分流术治疗肝硬化难治性胸水的疗效和安全性。
Liver Int. 2019 Nov;39(11):2164-2173. doi: 10.1111/liv.14200. Epub 2019 Aug 19.
4
The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation.术前肝性胸水对成人肝移植结局的影响。
Eur J Gastroenterol Hepatol. 2010 Feb;22(2):207-12. doi: 10.1097/MEG.0b013e3283311140.
5
Transjugular intrahepatic portosystemic shunt in refractory hydrothorax - a contribution to an unexplored indication.经颈静脉肝内门体分流术治疗难治性胸腔积液——对一个未被探索适应症的贡献
Eur J Gastroenterol Hepatol. 2016 Jun;28(6):661-6. doi: 10.1097/MEG.0000000000000623.
6
Analysis of clinical features and prognostic factors in patients with hepatic hydrothorax: a single-center study from China.分析中国单中心肝性胸水患者的临床特征和预后因素。
BMC Gastroenterol. 2022 Jul 7;22(1):333. doi: 10.1186/s12876-022-02412-9.
7
Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax.肝硬化合并肝性胸水住院患者 ACLF 风险增加和住院死亡率增加。
Dig Dis Sci. 2021 Oct;66(10):3612-3618. doi: 10.1007/s10620-020-06677-6. Epub 2020 Nov 13.
8
Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt.10mm 覆盖型经颈静脉肝内门体分流术后肝硬化患者的长期临床转归和生存预测因素。
Gastroenterol Hepatol. 2021 Nov;44(9):620-627. doi: 10.1016/j.gastrohep.2020.10.018. Epub 2020 Nov 26.
9
Repeat Thoracentesis in Hepatic Hydrothorax and Non-Hepatic Hydrothorax Effusions: A Case-Control Study.重复胸腔穿刺术治疗肝性胸水和非肝性胸水积液:一项病例对照研究。
Respiration. 2018;96(4):330-337. doi: 10.1159/000490001. Epub 2018 Jul 10.
10
Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax.经颈静脉肝内门体分流术与难治性肝性胸腔积液患者的肝移植
Liver Transpl Surg. 1998 Sep;4(5):416-23. doi: 10.1002/lt.500040506.